In Vitro Assessment of Cardiac Risk in Drug Discovery

Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic. Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).
Recommended Publications
Latest Publications
Metrion Biosciences High Throughput Screening Services

Here we share a short video introducing Metrion’s expanded high throughput screening capabilities. To learn more, or to request a quote, please email info@metrionbiosciences.com

Metrion Biosciences cardiac safety services overview

Here we share a short video introducing Metrion’s extensive suite of cardiac safety screening services. To learn more, or to request a quote, please email info@metrionbiosciences.com

View All
Secondary pharmacology publication recognised as ‘Most Impactful Publication of the Year’ by the Safety Pharmacology Society
Publication in support of refining the hERG testing strategy for silencing RNA (siRNA) receives ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society
View All
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram